M
MediWound
Focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management
About MediWound
MediWound is a biopharmaceutical company specializing in innovative solutions for burn wound care. The company focuses on developing and commercializing products for the removal of eschar, which is dead tissue that needs to be removed to promote healing in burn wounds. MediWound's core product, approved by the European Medicines Agency (EMA) in December 2012, targets adults with deep partial and full thickness thermal burns. The company operates a cGMP (current Good Manufacturing Practice) manufacturing facility that produces sterile pharmaceutical products, ensuring high-quality standards are met.
MediWound serves healthcare professionals and patients, primarily in the European market, but aims to expand globally. The business model revolves around the development, approval, and commercialization of its innovative drug products. Revenue is generated through the sale of these pharmaceutical products to hospitals and healthcare providers.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2000
- Headquarters
- Yavne, Israel
- Listing
- IPO 2014
- Employees
- 123
- Open positions
- 3
- Dealroom signal
- 75.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Dermatology, Spinout, Hospital, EIC, Biotech and Pharma, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $30M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Jul 2024 | $25M | — | Mölnlycke Health Care | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $24M | +42.3% | −$33M | -135.1% |
| 2025 | $17M | -16.1% | −$22M | -131% |
| 2024 | $20M | +8.2% | −$17M | -85.1% |
| 2023 | $19M | -29.5% | −$13M | -67.8% |
| 2022 | $26M | +11.5% | −$6.4M | -24.1% |
| 2021 | $24M | +9.2% | −$10M | -42% |
| 2020 | $22M | — | −$7.8M | -35.6% |
Growth signals
Latest recorded traffic for MediWound is 4.1K monthly website visits, down 35.9% over the last three months. MediWound's team grew 4.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
US Biomedical Advanced Research and Development Authority
US Department of War
European Innovation Council
Series A1 investor entered at this stage
Clal Biotechnology Industries
Other known investors7 additional known investors
Mölnlycke Health Care
Ben-Gurion University of the Negev
Deep Insight
Discount Capital
Israel Biotech Fund
New Era Capital- GGGandyr Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MediWound on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MediWound’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.